Blood Damage Models – Thrombosis

Objective:

The goal of this project is to generate physical test data for high-shear induced thrombosis events in a shear-controlled environment at appropriate length and time scales. The data collected would, at a minimum, include: a description of the flow conditions, initial thrombus formation location, rate of thrombus growth, and extent of thrombus. These data should be sufficient and robust enough to facilitate the development of computational models for thrombus formation. These data should also be reproducible and of appropriate accuracy for use in computational models.

Benefits of this work (with respect to the MDIC mission):

This project will provide foundational gold-standard data that currently does not exist in the public domain.  This data will help medical device developers understand and optimize thrombo-resistance during product development.  Ultimately, this will benefit the patient by enhancing medical device and technology evaluation. This work stream will feed into a subsequent effort to develop predictive computational models of thrombosis

Broad stakeholder engagement plan (dissemination beyond MDIC members):

During project planning stages, the group will solicit feedback from industry and subject matter experts through the MDIC.  Through MDIC, the group will also solicit participation in a multi-site study.  After completion of the work stream, the group will publish experimental details, protocols, blood-handling-procedures and results in peer-reviewed scientific journals, conferences, and/or other venues (e.g. public database library) to ensure scientific rigor, industry awareness, and broad access.

Deliverables:

Detailed description of the: blood collection and handling protocols, experimental geometric embodiment, blood flow rates and pressure losses along the experimental system, blood contacting surface properties (e.g. roughness and surface treatment), initial thrombus formation location, rate of thrombus growth, extent of thrombus, and any potential thrombus blood markers (e.g. plasma coagulation markers).

IP Considerations:

No attempt will be made to reverse engineer any devices/materials supplied by industry partners for the purpose of this project.